Yan Xiao-Qiang, Wang Zhong-Chang, Li Zhen, Wang Peng-Fei, Qiu Han-Yue, Chen Long-Wang, Lu Xiao-Yuan, Lv Peng-Cheng, Zhu Hai-Liang
State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210093, People's Republic of China.
State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210093, People's Republic of China.
Bioorg Med Chem Lett. 2015 Oct 15;25(20):4664-71. doi: 10.1016/j.bmcl.2015.08.026. Epub 2015 Aug 14.
New series of sulfonamide derivatives containing a dihydropyrazole moieties inhibitors of MMP-2/MMP-9 were discovered using structure-based drug design. Synthesis, antitumor activity, structure-activity relationship and optimization of physicochemical properties were described. In vitro the bioassay results revealed that most target compounds showed potent inhibitory activity in the enzymatic and cellular assays. Among the compounds, compound 3i exhibited the most potent inhibitory activity with IC50 values of 0.21 μM inhibiting MMP-2 and 1.87 μM inhibiting MMP-9, comparable to the control positive compound CMT-1 (1.26 μM, 2.52 μM). Docking simulation was performed to position compound 3i into the MMP-2 active site to determine the probable binding pose. Docking simulation was further performed to position compound 3i into the MMP-2 active site to determine the probable binding model the 3D-QSAR models were built for reasonable design of MMP-2/MMP-9 inhibitors at present and in future.
利用基于结构的药物设计发现了一系列含二氢吡唑部分的新型磺酰胺衍生物,它们是基质金属蛋白酶-2/基质金属蛋白酶-9的抑制剂。描述了其合成、抗肿瘤活性、构效关系及理化性质的优化。体外生物测定结果表明,大多数目标化合物在酶学和细胞试验中表现出较强的抑制活性。在这些化合物中,化合物3i表现出最强的抑制活性,其抑制基质金属蛋白酶-2的IC50值为0.21 μM,抑制基质金属蛋白酶-9的IC50值为1.87 μM,与对照阳性化合物CMT-1(1.26 μM,2.52 μM)相当。进行对接模拟将化合物3i定位到基质金属蛋白酶-2的活性位点,以确定可能的结合构象。进一步进行对接模拟将化合物3i定位到基质金属蛋白酶-2的活性位点,以确定可能的结合模型,目前和未来构建3D-QSAR模型用于合理设计基质金属蛋白酶-2/基质金属蛋白酶-9抑制剂。